Vertex Readies For Commercial Future For Multi-Therapeutic Area R&D Strategy
Executive Summary
Chief operating officer Stuart Arbuckle and chief scientific officer David Altshuler talked to Scrip about potential launches in sickle cell disease and pain, and the firm’s expanding pipeline.